The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Four physicians spoke on the panel, which was held at the Basketball Hall of Fame in Springfield, to discuss advancements in ...

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...

Veteran actor Sharmila Tagore was diagnosed with zero-stage lung cancer in 2023. Here's what the early-stage diagnosis means, how it was treated, and why early detection matters.

Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

“There are few treatment options for people living with this ... “The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s ...